Yüklüyor......
Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment...
Kaydedildi:
| Yayımlandı: | PLoS One |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Public Library of Science
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527782/ https://ncbi.nlm.nih.gov/pubmed/26247463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0133562 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|